Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Onconetix (ONCO) over the last 3 years, with Q3 2025 value amounting to -$1.9 million.

  • Onconetix's Gains from Investment Securities fell 1170307.18% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year decrease of 1180195.58%. This contributed to the annual value of $700124.0 for FY2024, which is 137026.19% up from last year.
  • Per Onconetix's latest filing, its Gains from Investment Securities stood at -$1.9 million for Q3 2025, which was down 1170307.18% from -$14010.0 recorded in Q2 2025.
  • Over the past 5 years, Onconetix's Gains from Investment Securities peaked at $512940.0 during Q2 2023, and registered a low of -$1.9 million during Q3 2025.
  • Its 3-year average for Gains from Investment Securities is -$110670.7, with a median of $326.5 in 2024.
  • Within the past 5 years, the most significant YoY rise in Onconetix's Gains from Investment Securities was 9890.81% (2025), while the steepest drop was 1170307.18% (2025).
  • Onconetix's Gains from Investment Securities (Quarter) stood at $47619.0 in 2023, then plummeted by 65.0% to $16668.0 in 2024, then tumbled by 11703.07% to -$1.9 million in 2025.
  • Its Gains from Investment Securities stands at -$1.9 million for Q3 2025, versus -$14010.0 for Q2 2025 and -$2472.0 for Q1 2025.